SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-365690
Filing Date
2017-12-11
Accepted
2017-12-11 09:54:55
Documents
3
Period of Report
2017-12-08
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d494470d8k.htm 8-K 33916
2 EX-3.1 d494470dex31.htm EX-3.1 6721
3 EX-3.2 d494470dex32.htm EX-3.2 38142
  Complete submission text file 0001193125-17-365690.txt   80619
Mailing Address 555 TWIN DOLPHIN DRIVE SUITE 615 REDWOOD CITY CA 94065
Business Address 555 TWIN DOLPHIN DRIVE SUITE 615 REDWOOD CITY CA 94065 6504750158
Ocera Therapeutics, Inc. (Filer) CIK: 0001274644 (see all company filings)

IRS No.: 631192270 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35119 | Film No.: 171248641
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences